March 7, 2016
Health Care Innovations

Introducing Bert Vrijhoef as our new CIO!

As of March 2015, we are delighted to welcome Prof. dr. Bert Vrijhoef as the Chief Innovation Officer (CIO) of Panaxea. Dr. Vrijhoef is a renowned international expert in the field of health care innovation and its scientific evaluation. Dr. Vrijhoef: “In my work I continuously strive to detect the […]
February 17, 2016

Three take home messages from the Economic Evaluation presentation

The new Dutch economic evaluation guideline was presented yesterday. Panaxea attended this meeting to be aware of this new guideline, and get familiair with the differences between this guideline and the previous edition. The guideline differs in many aspects from the 2006 version. We compiled a list of three changes […]
February 10, 2016
Health Technology Assessment

The new Dutch economic evaluation guideline

All parties in health care, from governments to hospitals, are bound to budgets. The use of economic evaluations helps these parties by determining how their budgets can be spend in the most optimal way. However, it is hard for some of these parties to make economic evaluations themselves or to […]
February 2, 2016

Panaxea takes place in CRADL consortium

Panaxea is proud to announce that it takes place in this consortium with 11 other parties, like the Middlesex University and Amsterdam’s Emma Children’s Hospital. CRADL (which stands for Continuous Regional Analysis Device for neonate Lung) will show how EID can provide new cost effective, easy to use, respiratory management […]
November 9, 2015

Panaxea posters, presentations and workshops @ISPOR Milan 9-11 November 2015

Dear ISPORIAN, Panaxea (www.panaxea.eu) provides customized, high-quality analyses about the added value of products and interventions in the care pathway. We specialize in health economic modeling for diagnostica and medical devices to facilitate market access in Europe. Curious to see how tools developed by Panaxea can be used for the […]
May 19, 2015

Health economic evaluation of a strict glucose control guideline implemented using point-of-care testing in three Intensive Care Units in the Netherlands

Health economic evaluation of a strict glucose control guideline implemented using point-of-care testing in three Intensive Care Units in the Netherlands van Hooijdonk RT1, Steuten LM, Kip MM, Monteban H, Mulder MR, van Braam Houckgeest F, van der Sluijs JP, Abu-Hanna A, Spronk PE, Schultz MJ.
May 19, 2015
Cost effective health model

Generic decision model for diagnostic tests

To give (potential) clients a preliminary insight in the cost-effectiveness of their diagnostic test, we developed an online generic decision model. This model allows users to compare the cost and effects of a diagnostic test versus not testing by using data they collected themselves, for example data they collected during […]
May 19, 2015

Marloes van der Maas joined board “Jong NVTAG”

Jong NVTAG is a Dutch organization that aims to address the need of young professionals in the field of health economics to meet each other, exchange experiences and learn more about the field. Jong NVTAG does this by organizing multiple events per year, each event centered on one theme that […]
April 20, 2015

Long-term cost–effectiveness of Oncotype DX® versus current clinical practice from a Dutch cost perspective

Michelle Kip, Helma Monteban & Lotte Steuten, Long-term cost–effectiveness of Oncotype DX® versus current clinical practice from a Dutch cost perspective, Journal of Comparative Effectiveness Research. Link to publication